Lynnette Samuel

Lynnette (Lynn) Samuel has over 30 years of experience in the pharmaceutical industry. Lynn worked for Abraxis BioScience, a parenteral drug manufacturer, for 27 years assuming roles of increasing responsibility which culminated in the leadership role of Sr. Director of the company’s Nanotechnology development Program. Lynn’s key achievement while at Abraxis was leading the activities in this capacity. Lynn was responsible for bringing a novel nanotechnology injectable drug formulation, Abraxane® for Injectable Suspension, from small-scale development and manufacturing, through full commercial scale-up, including leading the CMC development activities and eventual global launch in several countries around the world. Before Abraxis BioScience, Lynn worked for Cooper BioMedical and Baxter Laboratories in the manufacturing of diagnostic products. Lynn holds a B.A. in Business Management from Concordia University Wisconsin.